{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:56:49Z","timestamp":1791248209470,"version":"4.1.0"},"reference-count":78,"publisher":"Radiation Research Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiation Research"],"published-print":{"date-parts":[[2024,5,8]]},"abstract":"<jats:p>BBT-059, a long-acting PEGylated interleukin-11 (IL-11) analog that is believed to have hematopoietic promoting and anti-apoptotic properties, is being developed as a potential radiation medical countermeasure (MCM) for hematopoietic acute radiation syndrome (H-ARS). This agent has been shown to improve survival in lethally irradiated mice. To further evaluate the drug's toxicity and safety profile, 12 na\u00efve nonhuman primates (NHPs, rhesus macaques) were administered one of three doses of BBT-059 subcutaneously and were monitored for the next 21 days. Blood samples were collected throughout the study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of the drug as well as its effects on complete blood counts, cytokines, vital signs, and to conduct metabolomic studies. No adverse effects were detected in any treatment group during the study. Short-term changes in metabolomic profiles were present in all groups treated with BBT-059 beginning immediately after drug administration and reverting to near normal levels by the end of the study period. Several pathways and metabolites, particularly those related to inflammation and steroid hormone biosynthesis, were activated by BBT-059 administration. Taken together, these observations suggest that BBT-059 has a good safety profile for further development as a radiation MCM for regulatory approval for human use.<\/jats:p>","DOI":"10.1667\/rade-23-00194.1","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T20:00:35Z","timestamp":1715112035000},"page":"26-37","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic and Metabolomic Studies with a Promising Radiation Countermeasure, BBT-059 (PEGylated interleukin-11), in Rhesus Nonhuman Primates"],"prefix":"10.1667","volume":"202","author":[{"given":"Alana D.","family":"Carpenter","sequence":"first","affiliation":[{"name":"Division of Radioprotectants, Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Y.","family":"Wise","sequence":"additional","affiliation":[{"name":"Division of Radioprotectants, Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseyi O.","family":"Fatanmi","sequence":"additional","affiliation":[{"name":"Division of Radioprotectants, Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Petrus","sequence":"additional","affiliation":[{"name":"Division of Radioprotectants, Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Fam","sequence":"additional","affiliation":[{"name":"Bolder BioTechnology, Boulder, Colorado, 80301"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Bolder BioTechnology, Boulder, Colorado, 80301"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Cox","sequence":"additional","affiliation":[{"name":"Bolder BioTechnology, Boulder, Colorado, 80301"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita K.","family":"Cheema","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Radioprotectants, Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1243","reference":[{"key":"64","doi-asserted-by":"crossref","unstructured":"CA Smith, EJ Want, G O'Maille, et al.  \"Anal Chem.\"  78, \"XCMS: Processing mass spectrometry data for metabolite profiling using Nonlinear peak alignment, matching, and identification.\" 779 (2006)","DOI":"10.1021\/ac051437y"},{"key":"56","unstructured":"\"Guide for the care and use of laboratory animals.\"  (2011)"},{"key":"13","doi-asserted-by":"crossref","unstructured":"NP Clayton, RC Khan-Malek, CA Dangler, et al.  \"Radiat Res.\"  195, \"Sargramostim (rhu GM-CSF) improves survival of non-human primates with severe bone marrow suppression after acute, high-dose, whole-body irradiation.\" 191 (2021)","DOI":"10.1667\/RADE-20-00131.1"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Y Li, J Singh, R Varghese, et al.  \"Sci Rep.\"  11, \"Transcriptome of rhesus macaque (Macaca mulatta) exposed to total-body irradiation.\" 6295 (2021)","DOI":"10.1038\/s41598-021-85669-6"},{"key":"62","doi-asserted-by":"crossref","unstructured":"AK Cheema, Y Li, J Singh, et al.  \"Anim Microbiome.\"  3, \"Microbiome study in irradiated mice treated with BIO 300, a promising radiation countermeasure.\" 71 (2021)","DOI":"10.1186\/s42523-021-00132-1"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Y Li, M Girgis, SY Wise, et al.  \"Sci Rep.\"  11, \"Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure.\" 11449 (2021)","DOI":"10.1038\/s41598-021-91067-9"},{"key":"41","doi-asserted-by":"crossref","unstructured":"A Crook, A De Lima Leite, T Payne, et al.  \"Sci Rep.\"  11, \"Radiation exposure induces cross-species temporal metabolic changes that are mitigated in mice by amifostine.\" 14004 (2021)","DOI":"10.1038\/s41598-021-93401-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"JK Waselenko, TJ MacVittie, WF Blakely, et al.  \"Ann Intern Med.\"  140, \"Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group.\" 1037 (2004)","DOI":"10.7326\/0003-4819-140-12-200406150-00015"},{"key":"25","doi-asserted-by":"crossref","unstructured":"VK Singh  and TM Seed  \"Int J Radiat Biol.\"  93, \"A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.\" 851 (2017)","DOI":"10.1080\/09553002.2017.1332438"},{"key":"53","doi-asserted-by":"crossref","unstructured":"VK Singh, S Kulkarni, OO Fatanmi, et al.  \"Radiat Res.\"  185, \"Radioprotective efficacy of gamma-tocotrienol in nonhuman primates.\" 285 (2016)","DOI":"10.1667\/RR14127.1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"PA Plett, HL Chua, CH Sampson, et al.  \"Health Phys.\"  106, \"PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome.\" 7 (2014)","DOI":"10.1097\/HP.0b013e3182a4dd4e"},{"key":"51","doi-asserted-by":"crossref","unstructured":"VK Singh  and AO Olabisi  \"Expert Opin Drug Discov.\"  12, \"Nonhuman primates as models for the discovery and development of radiation countermeasures.\" 695 (2017)","DOI":"10.1080\/17460441.2017.1323863"},{"key":"16","doi-asserted-by":"crossref","unstructured":"AM Farese, MV Cohen, BP Katz, et al.  \"Radiat Res.\"  179, \"Filgrastim improves survival in lethally irradiated nonhuman primates.\" 89 (2013)","DOI":"10.1667\/RR3049.1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"AM Farese  and TJ MacVittie  \"Drugs Today (Barc).\"  51, \"Filgrastim for the treatment of hematopoietic acute radiation syndrome.\" 537 (2015)","DOI":"10.1358\/dot.2015.51.9.2386730"},{"key":"37","doi-asserted-by":"crossref","unstructured":"VP Kumar, S Biswas, NK Sharma, et al.  \"Health Phys.\"  115, \"PEGylated IL-11 (BBT-059): A novel radiation countermeasure for hematopoietic acute radiation syndrome.\" 65 (2018)","DOI":"10.1097\/HP.0000000000000841"},{"key":"12","doi-asserted-by":"crossref","unstructured":"KG Hankey, AM Farese, EC Blaauw, et al.  \"Radiat Res.\"  183, \"Pegfilgrastim improves survival of lethally irradiated nonhuman primates.\" 643 (2015)","DOI":"10.1667\/RR13940.1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"K Wong, PY Chang, M Fielden, et al.  \"Int J Radiat Biol.\"  96, \"Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates.\" 155 (2020)","DOI":"10.1080\/09553002.2019.1625488"},{"key":"23","doi-asserted-by":"crossref","unstructured":"VK Singh, M Garcia, TM Seed,  \"Int J Radiat Biol.\"  93, \"A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.\" 870 (2017)","DOI":"10.1080\/09553002.2017.1338782"},{"key":"44","doi-asserted-by":"crossref","unstructured":"VK Singh  and TM Seed  \"Expert Opin Drug Saf.\"  18, \"The efficacy and safety of amifostine for the acute radiation syndrome.\" 1077 (2019)","DOI":"10.1080\/14740338.2019.1666104"},{"key":"27","doi-asserted-by":"crossref","unstructured":"VK Singh  and TM Seed  \"Expert Opin Investig Drugs.\"  29, \"BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure.\" 429 (2020)","DOI":"10.1080\/13543784.2020.1757648"},{"key":"50","doi-asserted-by":"crossref","unstructured":"VK Singh  and M Hauer-Jensen  \"Int J Mol Sci.\"  17, \"Gamma-tocotrienol as a promising countermeasure for acute radiation syndrome: Current status.\" e663 (2016)","DOI":"10.3390\/ijms17050663"},{"key":"24","doi-asserted-by":"crossref","unstructured":"VK Singh, BK Hanlon, PT Santiago, et al.  \"Int J Radiat Biol.\"  93, \"A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with \u2018standard of care\u2019 medicinal and procedures not requiring regulatory approval for use.\" 885 (2017)","DOI":"10.1080\/09553002.2017.1332440"},{"key":"68","doi-asserted-by":"crossref","unstructured":"AK Cheema, CP Hinzman, KY Mehta, et al.  \"Int J Mol Sci.\"  19, \"Plasma derived exosomal biomarkers of exposure to ionizing radiation in nonhuman primates.\" 3427 (2018)","DOI":"10.3390\/ijms19113427"},{"key":"43","doi-asserted-by":"crossref","unstructured":"AK Cheema, Y Li, M Girgis, et al.  \"Sci Rep.\"  9, \"Metabolomic studies in tissues of mice treated with amifostine and exposed to gamma-radiation.\" 15701 (2019)","DOI":"10.1038\/s41598-019-52120-w"},{"key":"71","doi-asserted-by":"crossref","unstructured":"AK Cheema, KY Mehta, MU Rajagopal, et al.  \"Int J Mol Sci.\"  20, \"Metabolomic studies of tissue injury in nonhuman primates exposed to gamma-radiation.\" 3360 (2019)","DOI":"10.3390\/ijms20133360"},{"key":"46","doi-asserted-by":"crossref","unstructured":"AK Cheema, KY Mehta, PT Santiago, et al.  \"Int J Mol Sci.\"  20, \"Pharmacokinetic and metabolomic studies with BIO 300, a nanosuspension of genistein, in a nonhuman primate model.\" 1231 (2019)","DOI":"10.3390\/ijms20051231"},{"key":"57","doi-asserted-by":"crossref","unstructured":"M Girgis, Y Li, J Ma, et al.  \"Sci Rep.\"  10, \"Comparative proteomic analysis of serum from nonhuman primates administered BIO 300: a promising radiation countermeasure.\" 19343 (2020)","DOI":"10.1038\/s41598-020-76494-4"},{"key":"70","doi-asserted-by":"crossref","unstructured":"EL Pannkuk, EC Laiakis, VK Singh, et al.  \"Sci Rep.\"  7, \"Lipidomic signatures of nonhuman primates with radiation-induced hematopoietic syndrome.\" 9777 (2017)","DOI":"10.1038\/s41598-017-10299-w"},{"key":"48","doi-asserted-by":"crossref","unstructured":"EL Pannkuk, EC Laiakis, AJ Fornace, et al.  \"Health Phys.\"  115, \"A metabolomic serum signature from nonhuman primates treated with a radiation countermeasure, gamma-tocotrienol, and exposed to ionizing radiation.\" 3 (2018)","DOI":"10.1097\/HP.0000000000000776"},{"key":"69","doi-asserted-by":"crossref","unstructured":"EL Pannkuk, EC Laiakis, M Garcia, et al.  \"Radiat Res.\"  190, \"Nonhuman primates with acute radiation syndrome: Results from a global serum metabolomics study after 7.2 Gy total-body irradiation.\" 576 (2018)","DOI":"10.1667\/RR15167.1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"RP Gale  and JO Armitage  \"N Engl J Med.\"  378, \"Are we prepared for nuclear terrorism?\" 1246 (2018)","DOI":"10.1056\/NEJMsr1714289"},{"key":"8","unstructured":"DGC. McCann,  \"Am J Clin Med.\"  3, \"Radiation poisoning: Current concepts in the acute radiation syndrome.\" 13 (2006)"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Y Zhong, M Pouliot, AM Downey, et al.  \"Int J Radiat Biol.\"  97, \"Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model.\" S100 (2021)","DOI":"10.1080\/09553002.2019.1673499"},{"key":"15","doi-asserted-by":"crossref","unstructured":"VK Singh  and TM Seed  \"Drugs Today (Barc).\"  58, \"An update on romiplostim for treatment of acute radiation syndrome.\" 133 (2022)","DOI":"10.1358\/dot.2022.58.3.3367994"},{"key":"7","doi-asserted-by":"crossref","unstructured":"H Dorr  and V Meineke  \"BMC Med.\"  9, \"Acute radiation syndrome caused by accidental radiation exposure - therapeutic principles.\" 126 (2011)","DOI":"10.1186\/1741-7015-9-126"},{"key":"10","doi-asserted-by":"crossref","unstructured":"VK Singh  and TM. Seed  \"Drugs Today (Barc).\"  54, \"An update on sargramostim for treatment of acute radiation syndrome.\" 679 (2018)","DOI":"10.1358\/dot.2018.54.11.2899370"},{"key":"11","doi-asserted-by":"crossref","unstructured":"VK Singh  and TM. Seed  \"Int J Radiat Biol.\"  97, \"Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond.\" 1526 (2021)","DOI":"10.1080\/09553002.2021.1969054"},{"key":"61","doi-asserted-by":"crossref","unstructured":"S Kulkarni, PK Singh, SP Ghosh, et al.  \"Cytokine.\"  62, \"Granulocyte colony-stimulating factor antibody abrogates radioprotective efficacy of gamma-tocotrienol, a promising radiation countermeasure.\" 278 (2013)","DOI":"10.1016\/j.cyto.2013.03.009"},{"key":"55","doi-asserted-by":"crossref","unstructured":"AJ Phipps, JN Bergmann, MT Albrecht, et al.  \"Antimicrob Agents Chemother.\"  66, \"Model for evaluating antimicrobial therapy to prevent life-threatening bacterial infections following exposure to a medically significant radiation dose.\" e0054622 (2022)","DOI":"10.1128\/aac.00546-22"},{"key":"58","doi-asserted-by":"crossref","unstructured":"VK Singh, OO Fatanmi, SY Wise, et al.  \"Radiat Res.\"  198, \"Determination of lethality curve for cobalt-60 gamma-radiation source in rhesus macaques using subject-based supportive care.\" 599 (2022)","DOI":"10.1667\/RADE-22-00101.1"},{"key":"49","doi-asserted-by":"crossref","unstructured":"AK Cheema, KY Mehta, OO Fatanmi, et al.  \"Int J Mol Sci.\"  19, \"A Metabolomic and lipidomic serum signature from nonhuman primates administered with a promising radiation countermeasure, gamma-tocotrienol.\" 79 (2018)","DOI":"10.3390\/ijms19010079"},{"key":"26","doi-asserted-by":"crossref","unstructured":"VK Singh  and TM Seed  \"Expert Opin Investig Drugs.\"  32, \"Development of gamma-tocotrienol as a radiation medical countermeasure for the acute radiation syndrome: Current status and future perspectives.\" 25 (2023)","DOI":"10.1080\/13543784.2023.2169127"},{"key":"59","doi-asserted-by":"crossref","unstructured":"AK Cheema, Y Li, J Moulton, et al.  \"Int J Radiat Oncol Biol Phys.\"  114, \"Identification of novel biomarkers for acute radiation injury using multiomics approach and nonhuman primate model.\" 310 (2022)","DOI":"10.1016\/j.ijrobp.2022.05.046"},{"key":"1","doi-asserted-by":"crossref","unstructured":"AB Carter, MM May, WJ Perry,  \"Washington Quarterly.\"  30, \"The day after: Action following a nuclear blast in a U.S. city.\" 19 (2007)","DOI":"10.1162\/wash.2007.30.4.19"},{"key":"3","unstructured":"GC Benjamin, M McGeary, SR. McCutchen,  \"Topic 1: Effects of a 10-kt IND detonation on human health and the area of health care system. A Workshop Report.\"  7 (2009)"},{"key":"4","doi-asserted-by":"crossref","unstructured":"N Dainiak, JK Waselenko, JO Armitage, et al.  \"Hematology: American Society of Hematology Education Program.\"  2003, \"The hematologist and radiation casualties.\" 473 (2003)","DOI":"10.1182\/asheducation-2003.1.473"},{"key":"5","doi-asserted-by":"crossref","unstructured":"D Weisdorf, N Chao, JK Waselenko, et al.  \"Biol Blood Marrow Transplant.\"  12, \"Acute radiation injury: contingency planning for triage, supportive care, and transplantation.\" 672 (2006)","DOI":"10.1016\/j.bbmt.2006.02.006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"HM Lazarus, J McManus, RP. Gale,  \"Expert Opin Biol Ther.\"  22, \"Sargramostim in acute radiation syndrome.\" 1345 (2022)","DOI":"10.1080\/14712598.2022.2143261"},{"key":"19","doi-asserted-by":"crossref","unstructured":"DI Bunin, HS Javitz, J Gahagen, et al.  \"Int J Radiat Oncol Biol Phys.\"  17, \"Survival and hematologic benefits of romiplostim after acute radiation exposure supported FDA approval under the animal rule.\" 705 (2023)","DOI":"10.1016\/j.ijrobp.2023.05.008"},{"key":"20","unstructured":"\"Radiological and nuclear emergency preparedness information from FDA.\"  (2023)"},{"key":"21","unstructured":"Fresenius Kabi,  \"STIMUFEND (pegfilgrastim-fpgk) is biosimilar* to NEULASTA (pegfilgrastim).\"  (2023)"},{"key":"22","unstructured":"\"UDENYCA (pegfilgrastim-cbqv) is biosimilar* to NEULASTA (pegfilgrastim).\"  (2022)"},{"key":"28","doi-asserted-by":"crossref","unstructured":"RD Metcalfe, TL Putoczki, MDW Griffin,  \"Front Immunol.\"  11, \"Structural understanding of interleukin 6 family cytokine signaling and targeted therapies: Focus on interleukin 11.\" 1424 (2020)","DOI":"10.3389\/fimmu.2020.01424"},{"key":"29","doi-asserted-by":"crossref","unstructured":"VK Singh  and TM Seed  \"Expert Opin Drug Saf.\"  22, \"The safety and efficacy of interleukin 11 for radiation injury.\" 105 (2023)","DOI":"10.1080\/14740338.2023.2185604"},{"key":"30","doi-asserted-by":"crossref","unstructured":"H Dams-Kozlowska, K Gryska, E Kwiatkowska-Borowczyk, et al.  \"BMC Biotechnol.\"  12, \"A designer hyper interleukin 11 (H11) is a biologically active cytokine.\" 8 (2012)","DOI":"10.1186\/1472-6750-12-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"JA. Kaye,  \"Stem Cells.\"  14, \"The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).\" 256 (1996)","DOI":"10.1002\/stem.5530140733"},{"key":"32","unstructured":"CH. Reynolds,  \"Oncology (Williston Park).\"  14, \"Clinical efficacy of rhIL-11.\" 32 (2000)"},{"key":"33","doi-asserted-by":"crossref","unstructured":"AF Burnett, PG Biju, H Lui, et al.  \"Radiat Res.\"  180, \"Oral interleukin 11 as a countermeasure to lethal total-body irradiation in a murine model.\" 595 (2013)","DOI":"10.1667\/RR13330.1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"CS. Potten,  \"Stem Cells.\"  14, \"Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time.\" 452 (1996)","DOI":"10.1002\/stem.140452"},{"key":"35","unstructured":"TM Seed, CE Inal, JE. Deen,  \"48th Annual Meeting of the Radiation Research Society.\"  \"Assessment of a combined G-CSF plus IL-11 cytokine treatment for radiation-induced hematopoietic injury.\" 161 (2001)"},{"key":"36","doi-asserted-by":"crossref","unstructured":"J Hao, L Sun, H Huang, et al.  \"Radiat Res.\"  162, \"Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys.\" 157 (2004)","DOI":"10.1667\/RR3202"},{"key":"39","unstructured":"\"Pipeline.\"  (2017)"},{"key":"40","doi-asserted-by":"crossref","unstructured":"T Tuntland, B Ethell, T Kosaka, et al.  \"Front Pharmacol.\"  5, \"Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research.\" 174 (2014)","DOI":"10.3389\/fphar.2014.00174"},{"key":"52","unstructured":"\"Guidance for Industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.\"  (2005)"},{"key":"60","doi-asserted-by":"crossref","unstructured":"TK Garg, S Garg, IR Miousse, et al.  \"Int J Mol Sci.\"  \"Gamma-tocotrienol modulates total-body irradiation-induced hematopoietic injury in a nonhuman primate model.\" 23 (2022)","DOI":"10.3390\/ijms232416170"},{"key":"63","doi-asserted-by":"crossref","unstructured":"G Libiseller, M Dvorzak, U Kleb, et al.  \"BMC Bioinformatics.\"  16, \"IPO: a tool for automated optimization of XCMS parameters.\" 118 (2015)","DOI":"10.1186\/s12859-015-0562-8"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Y Chen, S Qin, Y Ding, et al.  \"Xenotransplantation.\"  16, \"Reference values of clinical chemistry and hematology parameters in rhesus monkeys (Macaca mulatta).\" 496 (2009)","DOI":"10.1111\/j.1399-3089.2009.00554.x"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Y Li, Q Wu, Y Jin, et al.  \"Vet Res.\"  50, \"Antiviral activity of interleukin-11 as a response to porcine epidemic diarrhea virus infection.\" 111 (2019)","DOI":"10.1186\/s13567-019-0729-9"},{"key":"72","doi-asserted-by":"crossref","unstructured":"AD Carpenter, Y Li, OO Fatanmi, et al.  \"Radiat Res.\"  \"Metabolomic profiles in tissues of nonhuman primates exposed to total- or partial-body radiation.\" (2024)","DOI":"10.1667\/RADE-23-00091.1"},{"key":"73","doi-asserted-by":"crossref","unstructured":"G. Reeves,  \"Health Phys.\"  106, \"Overview of use of G-CSF and GM-CSF in the treatment of acute radiation injury.\" 699 (2014)","DOI":"10.1097\/HP.0000000000000090"},{"key":"74","unstructured":"ME Vogel  and SD Zucker  \"Inflamm Cell Signal.\"  3, \"Bilirubin acts as an endogenous regulator of inflammation by disrupting adhesion molecule-mediated leukocyte migration.\" (2016)"},{"key":"75","doi-asserted-by":"crossref","unstructured":"W Stremmel, R Ehehalt, S Staffer, et al.  \"Digestive Diseases.\"  30, \"Mucosal Protection by Phosphatidylcholine.\" 85 (2013)","DOI":"10.1159\/000342729"},{"key":"76","doi-asserted-by":"crossref","unstructured":"K Mendelson, T Evans, T Hla,  \"Development.\"  141, \"Sphingosine 1-phosphate signal-ling.\" 5 (2014)","DOI":"10.1242\/dev.094805"},{"key":"77","doi-asserted-by":"crossref","unstructured":"T Mustelin, T Vang, N Bottini,  \"Nat Rev Immunol.\"  5, \"Protein tyrosine phosphatases and the immune response.\" 43 (2005)","DOI":"10.1038\/nri1530"},{"key":"78","doi-asserted-by":"crossref","unstructured":"VK Singh, AD Carpenter, BL Janocha, et al.  \"Expert Opin Drug Discov.\"  18, \"Radiosensitivity of rhesus nonhuman primates: Consideration of sex, supportive care, body weight and age at time of exposure.\" 797 (2023)","DOI":"10.1080\/17460441.2023.2205123"},{"key":"42","doi-asserted-by":"crossref","unstructured":"AK Cheema, Y Li, M Girgis, et al.  \"Metabolites.\"  10, \"Alterations in tissue metabolite profiles with amifostine-prophylaxed mice exposed to gamma radiation.\" 211 (2020)","DOI":"10.3390\/metabo10050211"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Y Li, M Girgis, M Jayatilake, et al.  \"Sci Rep.\"  12, \"Pharmacokinetic and metabolomic studies with a BIO 300 oral powder formulation in nonhuman primates.\" 13475 (2022)","DOI":"10.1038\/s41598-022-17807-7"},{"key":"65","doi-asserted-by":"crossref","unstructured":"WB Dunn, D Broadhurst, P Begley, et al.  \"Nat Protoc.\"  6, \"Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry.\" 1060 (2011)","DOI":"10.1038\/nprot.2011.335"}],"container-title":["Radiation Research"],"original-title":[],"link":[{"URL":"https:\/\/meridian.allenpress.com\/radiation-research\/article-pdf\/doi\/10.1667\/RADE-23-00194.1\/3369342\/10.1667_rade-23-00194.1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/radiation-research\/article-pdf\/doi\/10.1667\/RADE-23-00194.1\/3369342\/10.1667_rade-23-00194.1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:42:27Z","timestamp":1791247347000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/radiation-research\/volume-202\/issue-1\/RADE-23-00194.1\/Pharmacokinetic-and-Metabolomic-Studies-with-a-Promising-Radiation-Countermeasure-BBT\/10.1667\/RADE-23-00194.1.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1667\/rade-23-00194.1","relation":{},"ISSN":["0033-7587","1938-5404"],"issn-type":[{"value":"0033-7587","type":"print"},{"value":"1938-5404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]}}}